|
1
|
Coronary intervention for persistent occlusion after myocardial infarction.
|
N Engl J Med
|
2006
|
8.74
|
|
2
|
Coronary bypass surgery with or without surgical ventricular reconstruction.
|
N Engl J Med
|
2009
|
7.71
|
|
3
|
Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction.
|
N Engl J Med
|
2006
|
3.56
|
|
4
|
Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction.
|
Circulation
|
2008
|
2.59
|
|
5
|
Navigating the crossroads of coronary artery disease and heart failure.
|
Circulation
|
2006
|
2.06
|
|
6
|
Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study.
|
JACC Cardiovasc Interv
|
2008
|
1.63
|
|
7
|
Comparison of outcomes of patients with myocardial infarction when living alone versus those not living alone.
|
Am J Cardiol
|
2002
|
1.60
|
|
8
|
Over 10 years with an implantable cardioverter-defibrillator - a long term follow-up of 60 patients.
|
Kardiol Pol
|
2010
|
1.40
|
|
9
|
Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur?
|
Cardiovasc Drugs Ther
|
2004
|
1.39
|
|
10
|
Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial.
|
Eur J Heart Fail
|
2010
|
0.89
|
|
11
|
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical trials.
|
Am Heart J
|
2005
|
0.88
|
|
12
|
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial.
|
JAMA
|
2002
|
0.87
|
|
13
|
Impact of stress testing before percutaneous coronary intervention or medical management on outcomes of patients with persistent total occlusion after myocardial infarction: analysis from the occluded artery trial.
|
Am Heart J
|
2009
|
0.80
|
|
14
|
Evaluation of the functional status questionnaire in heart failure: a sub-study of the second cardiac insufficiency bisoprolol survival study (CIBIS-II).
|
Cardiovasc Drugs Ther
|
2011
|
0.80
|
|
15
|
Mortality in patients with heart failure treated with cardiac resynchronisation therapy. A long-term multi-centre follow-up study.
|
Kardiol Pol
|
2007
|
0.77
|
|
16
|
Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the Occluded Artery Trial (OAT) biomarker ancillary study.
|
BMC Cardiovasc Disord
|
2013
|
0.75
|
|
17
|
Use of fly ash agglomerates for removal of arsenic.
|
Environ Geochem Health
|
2010
|
0.75
|
|
18
|
[Development of nitrate tolerance in individual patients with stable angina pectoris in various phases of therapy with oral isosorbide dinitrate].
|
Pol Merkur Lekarski
|
2002
|
0.75
|
|
19
|
[Clinical evaluation of pentaerythritol tetranitrate in two doses in patients with stable angina pectoris].
|
Przegl Lek
|
2005
|
0.75
|
|
20
|
[Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
|
Pol Arch Med Wewn
|
2002
|
0.75
|
|
21
|
[Clinical usefulness of high-dose oral nitroglycerin in patients with stable angina pectoris].
|
Wiad Lek
|
2003
|
0.75
|
|
22
|
A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early ST-segment resolution after fibrinolytic therapy: the ExTRACT-TIMI 25 ECG study.
|
Eur Heart J
|
2007
|
0.75
|
|
23
|
Calcium blocker therapy before myocardial infarction increases post-infarction short- and long-term mortality. Data from the INJECT trial.
|
Kardiol Pol
|
2002
|
0.75
|